eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

without publication fees

Open access

without publication fees
1/2024
vol. 40
 
Share:
Send email
Share:
Review article

Lecanemab in the treatment of early Alzheimer’s disease – a review of the literature

Wiktor Szymajda
1
,
Łukasz Salamaga
1
,
Weronika Skoczek
1
,
Bartosz Zaleski
1
,
Mikołaj Araszewski
1
,
Ada Kaczmarek
1, 2
,
Grzegorz Kolasa
2

  1. Faculty of Medicine, Poznan University of Medical Sciences, Poznan, Poland
  2. Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
Farmakoterapia w Psychiatrii i Neurologii 2024, 40 (1), 31–42
DOI: https://doi.org/10.5114/fpn.2024.140847
Online publish date: 2024/08/01
Article file
- 04_IPiN_FARM_2024-1C_Lecanemab.pdf  [0.17 MB]
Get citation
 
PlumX metrics:
 
1. Alzforum [Internet]. Leqembi. Available from: https://www.alzforum.org/therapeutics/leqembi (last accessed on 12.05.2023).
2. Alzheimer’s Association. 2021 Alzheimer’s disease facts and figures. Alzheimers Dement. 2021; 17: 327–406
3. Bello AM, Olalekan SK, Azizah U, Wael M, Haziq K, Husna IN et al. Alzheimer’s Disease: An Update and Insights Into Pathophysiology. Front Aging Neurosci. 2022; 14: 742408.
4. Cummings J, Salloway S. Aducanumab: Appropriate use recommendations. Alzheimers Dement. 2022; 18: 531–533.
5. Food and Drug Administration. FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval [Internet]. Available from: https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval (last accessed on 23.06.2023). (a)
6. Food and Drug Administration. FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment [Internet]. Available from: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimersdisease-treatment (last accessed on 08.08.2023). (b)
7. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11: S33–39.
8. Hoy SM. Lecanemab: First Approval. Drugs. 2023; 83: 359–365.
9. Husain MA, Laurent B, Plourde M. APOE and Alzheimer’s Disease: From Lipid Transport to Physiopathology and Therapeutics. Front Neurosci 2021; 15: 630502.
10. InformedHealth.org [Internet]. Non-drug interventions for Alzheimer’s disease. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279355/ (last accessed on 04.06.2023).
11. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015; 11(1): 1–15.e1–4.
12. McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M et al. Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther 2022; 14: 191.
13. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging – Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7: 263–269.
14. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11: S13–21.
15. National Institute of Aging [Internet]. Available from: https://www.nia.nih.gov/health/how-alzheimers-diseasetreated (last accessed on 25.06.2023).
16. Młynarczyk R, Bochon B, Piontek A, Kunert Ł, Sobiś J, Gorczyca PW. Choroba Alzheimera – nowe strategie leczenia. Psychiatr. 2016; 13: 210–214.
17. Marasco RA. Current and evolving treatment strategies for the Alzheimer disease continuum. Am J Manag Care 2020; 26: S167-S176.
18. Söderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G et al. Lecanemab, Aducanumab, and Gantenerumab – Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease. Neurotherapeutics. 2023; 20: 195–206.
19. Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK et al. A randomized, double-blind, phase 2b proofof- concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021; 13: 80. Erratum in: Alzheimers Res Ther. 2022.
20. Tahami Monfared AA, Tafazzoli A, Ye W, Chavan A, Zhang Q. Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling. Neurol Ther. 2022; 11: 863–880.
21. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med 2023; 388: 9–21.
22. Vaz M, Silva V, Monteiro C, Silvestre S. Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities. Clin Interv Aging. 2022; 17: 797–810.
23. Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer’s disease trials. J Neurol Neurosurg Psychiatry 2016; 87: 993–999.
24. Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: An update. J. Cent. Nerv. Syst. Dis. 2020; 12: 1179573520907397.

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.